What is the most common secondary cancer with CLL?
The second cancers that are seen most frequently in CLL patients are acute myeloid leukemia, myelodysplastic syndromes, melanoma, gastrointestinal cancer, breast cancer, lung cancer, non-melanoma skin cancer, prostate cancer, kidney cancer, bladder cancer, and head and neck cancers.
Can CLL turn into something else?
Most commonly, CLL transforms into diffuse large B-cell lymphoma (DLBCL), which is a more aggressive non-Hodgkin lymphoma. Rarely, CLL can also transform into Hodgkin lymphoma or another type of aggressive lymphoma.
What percentage of CLL patients get a secondary cancer?
The researchers studied 1,069 patients diagnosed with CLL at M. D. Anderson between 1985 and 2001. None of the patients had a history of cancer, and all were followed for at least one year. By a mean follow-up of six years, sixty-six patients (6%) had been diagnosed with secondary invasive cancers.
Falchi L et al.  reported that the overall prevalence of secondary cancers was 36% in patients with CLL, among which the most common secondary cancer is non-melanoma skin cancer followed by prostate cancer.
Can CLL turn into AML?
Acute myeloid leukemia (AML) is another rare complication in patients who have been treated for CLL. Drugs such as chlorambucil and cyclophosphamide can damage the DNA of blood-forming cells. These damaged cells may go on to become cancer, leading to AML, which is very aggressive and often hard to treat.
How do I know if my CLL is getting worse?
Another symptom of CLL progression is extreme fatigue and shortness of breath while doing your normal day-to-day activities. This is due to fewer healthy red blood cells and more cancer cells accumulating in your body.
Does CLL make you more susceptible to other cancers?
In fact, certain types of cancer and cancer treatments can be linked to a higher risk of certain second cancers. People with CLL can get any type of second cancer, but they have an increased risk of: Skin cancer. Melanoma of the skin.
Does leukemia lead to other cancers?
Chronic myeloid leukemia (CML) can become resistant to treatment and progress to more advanced phases. But sometimes people with CML or develop a new, unrelated cancer later. This is called a second cancer. No matter what type of cancer you have or had, it’s still possible to get another (new) cancer.
Can CLL metastasize?
Rai stage IV: Lymphocytosis; enlarged lymph nodes, spleen, or liver; red blood cell counts may be low or near normal; platelet counts are low (thrombocytopenia).
Does CLL affect the brain?
Chronic lymphocytic leukemia can certainly invade into the fluid lining the brain and possibly the lining of the brain itself. The absolute best way to evaluate this possibility would be to perform a lumbar puncture (spinal tap) to directly look for the CLL cells in the cerebrospinal fluid.
Can you get lung cancer from CLL?
Conclusions: Approximately 2% of patients with CLL develop lung carcinoma. In this study, 85% of the patients were smokers. These patients had a high risk of a third primary malignancy. Lung carcinoma was diagnosed a decade after CLL.
Can CLL cause colon cancer?
One of the complications of B cell CLL is an associated increased risk of subsequent second malignancies, most commonly melanoma, soft-tissue sarcoma and colorectal and lung carcinoma [2-4]. Immunosuppression associated with the long term nature of B cell CLL has been proposed as the basis of this increased risk [5,6].
Does smoking make CLL worse?
The risk of CLL does not seem to be linked to smoking, diet, or infections.
Can leukemia cause secondary cancers?
Patients with chronic myeloid leukemia (CML) have a 30% higher risk of developing a secondary cancer compared with the general population, and the risk is highest within the first year of diagnosis, according to an observational study published in PeerJ.
Can CLL cause multiple myeloma?
Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both cancers is rare, and data on clinical outcomes and the management of these concurrent disease are limited.